FOR PATIENTS
FOR CLINICIANS
FOR THE PRESS
THE EXPERTS GROUP
MEDIA POOL
> SIRT > Home > Information library
 

INFORMATION LIBRARY

Here is where you will find an in-depth fact sheet on Selective Internal Radiation Therapy, image material and the CVs of the members of the Selective Internal Radiation Therapy Experts Group.

Fact sheet on Selective Internal Radiation Therapy (SIRT)

Presentation from the satellite symposium “SIR-Spheres Y-90 resin microspheres – the time to start is now” at the 18th ESMO World Congress on Gastrointestinal Cancers (WCGIC) on 1 July 2016 in Barcelona:

Presentation from the satellite symposium “SIR-Spheres Y-90 resin microspheres – evidence-based radiotherapy targeted at the liver” at the 32nd German Cancer Congress on 24.02.2016 in Berlin:

Die radioaktiven Mikrokügelchen werden in den Katheter geleitet

Photo 1
The radioactive microspheres are injected via a catheter into the hepatic artery.

Eine mikroskopische Aufnahme der mit Yttrium-90 markierten Mikrokugeln

Photo 2
A microscopic snapshot of the microspheres labelled with yttrium-90

Der Weg des Katheters bei der Selektiven Internen Radiotherapie

Graphic 1
The route of the catheter during Selective Internal Radiation Therapy

Die radioaktiven Mikrokügelchen gelangen in den Tumor.

Graphic 2
The radioactive microspheres make their way into the tumour.

Die radioaktiven Mikrokügelchen geben ihre Strahlung ab und zerstören den Tumor von innen heraus.

Graphic 3
The radioactive microspheres release their radiation and destroy the tumour from within.

 
NEWS & DATES
More treatment options are necessary for patients with metastatic colorectal cancer – Colorectal cancer prevention is getting more and more attention. However, every third colorectal cancer patient develops metastases in the course of the disease – often in the liver. For these patients, more and better therapy options are needed. Local therapies offer promising opportunities.To the press release
The new ESMO guidelines recommend SIRT for people with metastatic colorectal cancer if the metastases are limited to the liver and are not responding to chemotherapy.
New evidence of the benefits of SIRT in mCRC – The depth-of-response data from the SIRFLOX study shows a significantly larger local depth of response through the combination of SIRT and chemotherapy. To the press release
Metastatic colorectal cancer: the SIRFLOX, FOXFIRE and FOXFIRE Global studies are investigating the benefits of combining SIRT with chemotherapy. The data from the three studies regarding overall survival is expected by the end of 2017. The SARAH and SIRveNIB studies on advanced liver cell cancer are now complete. Both compared Y90 radio-embolisation with sorafenib chemotherapy. The initial results are set to be published at the end of 2016 (SARAH) and 2017 (SIRveNIB).
The SIRT Experts Group is a partner of:
For further professional information, please log in here:
If you do not have DocCheck access, please contact us. We will be happy to help.